Hims & Hers Health, Inc. (HIMS)
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $19.33, denoting a -16.05% move from the preceding trading day.
Hims & Hers Health: Don't Fall For The Hysteria
Hims & Hers Health trades at yearly lows amid market hysteria over compounded oral Wegovy and regulatory scrutiny. The online health platform is not a GLP-1-centric company; weight-loss sales are forecast at only 30% of 2025 revenue, with a broader focus on preventative care and platform growth. Recent FDA and Novo Nordisk actions should have limited impact, as HIMS already pulled the oral Wegovy, and the market has overreacted to worst-case scenarios.
Novo Nordisk's latest salvo against Hims & Hers—a patent-infringement lawsuit—shows the fierce maneuvering over the booming obesity-drug market
The Danish drugmaker's patent lawsuit is the company's latest effort to shore up its place in the booming weight-loss drug market.
Hims & Hers Stock Plunges While Novo Nordisk Gains as Weight-Loss Drug Wars Take New Turn
Hims & Hers Health shares are tumbling after a major blow to its weight-loss lineup.
Hims & Hers is scrapping its plan for a knockoff Wegovy weight-loss pill. Here's why
Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug and one day after the Food and Drug Administration threatened to restrict access to the ingredients needed to copy popular weight-loss medications.Hims had said Thursday that it would offer a compounded version of the new Wegovy pill that drugmaker Novo Nordisk just began selling last month. Novo immediately threatened to sue Hims, and then the FDA said Friday that it plans to take decisive steps to limit access to the active ingredients in popular GLP-1 drugs like Wegovy, Ozempic and Zepbound.Hims' own website still touted the new semaglutide pill offering Saturday afternoon — hours after it announced on X that it will no longer sell the medicine.
HIMs 22% Collapse Looks Like A ‘Buy The Dip' Moment
Shares of Hims & Hers Health (NYSE:HIMS) plunged 22% at market open on Monday, February 9.
Hims & Hers Falls Apart, Again
Hims & Hers Health (NASDAQ: HIMS) has had among the worst runs of any public company over the last year.
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hims & Hers scraps low-cost weight-loss pill following backlash
Hims & Hers scraps low-cost weight-loss pill following backlash Him & Hers (NYSE:HIMS) shares are set to open 23% lower at about $18 after the telehealth company announced over the weekend that it will stop offering a compounded oral version of semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, following regulatory scrutiny and industry backlash. “Since launching the compounded semaglutide pill on our platform, we've had constructive conversations with stakeholders across the industry,” Hims & Hers said in a statement on Saturday.
Novo Nordisk sues Hims & Hers over patent infringement
Novo Nordisk said on Monday it has filed a lawsuit against U.S. telehealth company Hims & Hers for infringing on the Danish group's patents.
Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injections
Novo Nordisk is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe on the company's patents, and is seeking to recover damages. The move escalates the feud between Novo and Hims, which said on Saturday it will stop offering its newly launched obesity pill copycat after facing scrutiny from federal regulators and legal threats from the Danish drugmaker.
Wall Street Breakfast Podcast: HIMS Loses Weight In Premarket Trade
Hims & Hers Health (HIMS) drops 15% premarket after halting compounded Wegovy pill sales amid FDA scrutiny and Novo Nordisk pressure. Samsung (SSNLF) surges on imminent HBM4 chip mass production, reportedly shipping to Nvidia for next-gen AI accelerators.
